05.07.19
Sanofi
1Q Revenues: €8.4 billion (+6%)
1Q Earnings: €1.8 billion (+11%)
Comments: Pharmaceutical sales were €6.3 billion in the quarter, up 3%. Genzyme sales were up 31% to €2.0 billion, driven by Dupixent, with sales of €329 million, and consolidation of Bioverativ. Vaccines sales were up 21% to €873 million, reflecting growth of Pentaxim in China and Menactra in Emerging Markets. Primary Care sales were down 17% to €2.3 billion impacted by lower diabetes sales and divestiture of EU generics. Established product sales were down 9% to €2.5 billion. Lovenox sales were down 12% to €343 million, due to biosimilar competition in several countries in Europe. Plavix sales were up 3% to €404 million. Aprovel/Avapro sales were up 15% to €201 million. Renvela/Renagel sales were down 26% to €79 million due to generic competition in the U.S.
1Q Revenues: €8.4 billion (+6%)
1Q Earnings: €1.8 billion (+11%)
Comments: Pharmaceutical sales were €6.3 billion in the quarter, up 3%. Genzyme sales were up 31% to €2.0 billion, driven by Dupixent, with sales of €329 million, and consolidation of Bioverativ. Vaccines sales were up 21% to €873 million, reflecting growth of Pentaxim in China and Menactra in Emerging Markets. Primary Care sales were down 17% to €2.3 billion impacted by lower diabetes sales and divestiture of EU generics. Established product sales were down 9% to €2.5 billion. Lovenox sales were down 12% to €343 million, due to biosimilar competition in several countries in Europe. Plavix sales were up 3% to €404 million. Aprovel/Avapro sales were up 15% to €201 million. Renvela/Renagel sales were down 26% to €79 million due to generic competition in the U.S.
